DCAT Value Chain Insights’ Production to Prescription
New Excipient Products: Are They Coming?
Aug 13, 202632 min
Support the show
Loading…
Loading…
business
Hosted by DCAT · business · EN-US · 60 episodes
DCAT Value Chain Insights' Production to Prescription podcast, presented by the Drug, Chemical & Associated Technologies Association (DCAT), features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
32%
Guest openness
Selective
Sign up to generate a grounded pitch for DCAT Value Chain Insights’ Production to Prescription.
Signup to Generate a PitchDCAT Value Chain Insights’ Production to Prescription is a business podcast hosted by DCAT, with 60 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.
DCAT hosts DCAT Value Chain Insights’ Production to Prescription, a business show with 60 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
DCAT Value Chain Insights’ Production to Prescription
Support the show
DCAT Value Chain Insights’ Production to Prescription
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have been several large deals among the bio/pharma majors and smaller innovator companies, with one drug candidate recently gaining FDA approval. What is the market potential and both the promise and limitations of these drug classes? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest insights. Support the show
DCAT Value Chain Insights’ Production to Prescription
<p>As the industry reaches the mid-point in 2026, how are CDMOs of small-molecule drugs faring? The larger scale CDMOs with late-phase and/or commercial-scale capabilities are faring well while smaller and mid-sized CDMOs specializing in early-stage development and clinical-scale capabilities are facing some headwinds from more challenging trends in biotech financing, but opportunities lie ahead. Brian Scanlan, Managing Partner, Freedom Bioscience Partners, a strategic advisory firm to CROs, CDMOs, and investors, provides the latest insights.</p><p>Support the show</p>
DCAT Value Chain Insights’ Production to Prescription
<p>Support the show</p>
DCAT Value Chain Insights’ Production to Prescription
<p>As bio/pharma companies and their suppliers set and implement their sustainability strategies, what issues top the industry’s sustainability agenda? Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026. Dr. Ute Schleyer, Vice President, Internal Project Management and EHS Sustainability, Vetter, provides key insights on how bio/pharmaceutical companies and their suppliers are collaborating and the sustainability frameworks supporting these efforts.</p><p>Support the show</p>
Recent guests on DCAT Value Chain Insights’ Production to Prescription. Study who booked and why before you pitch.
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
